Adenovirus-vectored vaccines

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 3, 2008, Pages 293-307

  Chawla, Tanu ^a   Khanna, Navin ^a   Swaminathan, Sathyamangalam ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Adenovirus; AIDS; Dengue; Malaria; Prior immunity; Tuberculosis; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; ALZHEIMER DISEASE VACCINE; AMYLOID BETA ANTIGEN; ANTHRAX VACCINE; BCG VACCINE; CARCINOEMBRYONIC ANTIGEN; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; EBOLA VACCINE; GAG PROTEIN; GLYCOPROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; NEF PROTEIN; POL PROTEIN; PROTOZOAL VACCINE; PSEUDOMONAS VACCINE; RABIES VACCINE; RECOMBINANT VACCINE; RTSS VACCINE; SUBUNIT VACCINE; TELOMERASE REVERSE TRANSCRIPTASE; TETANUS TOXOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTHRAX; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COSMID; DRUG SYNTHESIS; GENE EXPRESSION; GENOME ANALYSIS; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFLUENZA; INFLUENZA VIRUS A H5N1; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NONHUMAN; PATENT; RABIES; REVIEW; TRANSGENE; VIRUS GENOME; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS RECOMBINATION; VIRUS REPLICATION;

EID: 42549145565     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.3.293     Document Type: Review

References (123)

1. Polo JM, Dubensky TW Jr. Virus-based vectors for human vaccine applications. Drug Disc Today 2002;7:719-27
2. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Ann Rev Med 2004;55:355-72
3. Barouch DH. Rational design of gene-based vaccines. J Pathol 2006;208:283-9
4. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Ann Rev Biochem 2005;74:711-38
5. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005;16:149-56
6. Russell KL, Hawksworth AW, Ryan MAK, et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine 2006;24:2835-42
7. Kitchen LW, Vaughn DW. Role of US military research programs in the development of US-licensed vaccines for naturally occurring infectious diseases. Vaccine 2007;24:7017-30
8. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999;10:440-7
9. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006;24:849-62
10. Schagen FHE, Ossevoort M, Toes REM, Hoeben RC. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 2004;50:51-70
11. Shenk T. Adenoviridae: the viruses and their replication. In: Field's Virology. Knipe DM, Howley PM, editors. Lippincott Williams & Wilkins, Philadelphia: PA; 2001. p. 2265-300
12. Leopold PL, Crystal RG. Intracellular trafficking of adenovirus: many means to an end. Adv Drug Deliv Rev 2007;59:810-21
13. Swaminathan S, Thimmapaya B. Transactivation of adenovirus E2 early promoter by E1A and E4 6/7 in the context of viral chromosome. J Mol Biol 1996;258:736-46
14. Centers for Disease Control & Prevention/Purdue Research Foundation. Vaccine against pandemic strains of influenza viruses. WO2006113214 (2006)
15. Graham FL, Smiley J, Russell WC, Naim R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-72
16. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: A new helper cell line for the titration and propagation of early-region-1-deleted adenoviral vectors. Hum Gene Ther 1996;7:215-22
17. Fallaux FJ, Bout A, Van Der Velde I, et al. Helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998;9:1909-17
18. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996;70:7030-8
19. Zhou H, Beaudet AL. A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors. Virology 2000;275:348-57
20. Yeh P, Dedieu JF, Orsini C, et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996;70:559-65
21. Gorziglia MI, Kadan MJ, Yei S, et al. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996;70:4173-8
22. Gorziglia MI, Lapcevich C, Roy S, et al. Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3. J Virol 1999;73:6048-55
23. Mizuguchi H, Kay MA, Hayakawa T. Approaches for generating recombinant adenovirus vectors. Adv Drug Deliv Rev 2001;52:165-76
24. Ketner G, Spencer F, Tugendreich S, et al. Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. Proc Natl Acad Sci USA 1994;91:6186-90
25. He TC, Zhou S, Da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509-14
26. Mcgrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 1988;163:614-7
27. Genphar, Inc. Genetic vaccine against human immunodeficiency virus. WO03038057 (2003)
28. National Institute of Immunology (India). Recombinant vaccine against Japanese Encephalitis Virus [JEV] infection and a method thereof. WO2005065707 (2005)
29. National Institutes of Health. New adenovirus type 7 vectors. WO2003020893 (2003)
30. Anderson RD, Haskell RE, Xia H, et al. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 2000;7:1034-8
31. Merck & Co., Inc. Adenovirus carrying Gag gene HIV vaccine. WO0102607 (2001)
32. Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications. WO02022080 (2002)
33. Fundacao Oswaldo Cruz-Fiocruz. Construction of recombinant adenovirus with genes that codify for SAG1, SAG2 and SAG3. WO2007051271 (2007)
34. Genexine, Inc. A vaccine enhancing the protective immunity to hepatitis C virus using plasmid DNA and recombinant adenovirus. WO2004028563 (2004)
35. Vaxin, Inc. System for rapid production of high titer and replication-competent adenovirus-free recombinant adenovirus vectors. WO2006127956 (2006)
36. Genstar Therapeutics. Minimal adenovirus-mediated recombinant vaccines. WO0231168 (2002)
37. Hardy S, Kitamura M, Harris-Stansil T, et al. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997;71:1842-9
38. Zou L, Zhou H, Pastore L, Yang K. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther 2000;2:105-13
39. Merck & Co., Inc. A system for production of helper dependent adenovirus vectors based on use of endonucleases. WO0049166 (2000)
40. International AIDS Vaccine Initiative (LAVI). Special issue, AIDS Vaccine Bulletin (2006). Available from: www.iavireport.org/vax/english/ vax.2006.jan.cvrs.web.pdf [Last accessed 22 January 2008]
41. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006;24:4062-81
42. US National Library of Medicine clinical alert: immunizations are discontinued in two HIV vaccine trials. NIH/NIAID Advisory. 2007. Available from: www.nlm.nih.gov/databases/alerts/hiv_step_study.html [Last accessed 22 January 2008]
43. IAVI. Special bulletin. IAVI Rep 2007;11(5). Available from: www.iavireport.org/Issues/Issue11-5/Step.asp [Last accessed 22 January 2008]
44. National Institutes of Health/Genvec, Inc. Method of using adenoviral vectors to induce an immune response. WO2005110492 (2005)
45. Santra S, Seaman MS, Xu L, et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005;79:6516-22
46. Catanzaro AT, Koup RA, Roederer M, et al. Phase I safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006;194:1638-49
47. Malkevitch NV, Robert-Guroff M. A call for replicating vector prime/ protein boost strategies in HIV/vaccine design. Exp Rev Vaccines 2004;3(Suppl):89-101
48. Gomez-Roman VR, Grimes GJ Jr, Potti GK, et al. Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine 2006;24:5064-72
49. Matsui M, Moriya O, Alcatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 2003;21:1629-39
50. Arribillaga L, De Cerio AL, Sarobe P, et al. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recambinant vaccinia virus. Vaccine 2002;21:202-10
51. Merck & Co., Inc. Hepatitis C virus vaccine. WO03031588 (2003)
52. Jaiswal S, Khanna N, Swaminathan S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol 2003;77:12907-13
53. Khanam S, Khanna N, Swaminathan S. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 2006;24:6513-25
54. Khanam S, Rajendra P, Khanna N, Swaminathan S. An adenovirus prime/ plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol 2007;7:10
55. Raja NU, Holman DH, Wang D, et al. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. Am J Trop Med Hyg 2007;76:743-51
56. Pereboev A, Borisevich V, Tsuladze G, et al. Genetically delivered antibody protects against West Nile virus. Antiviral Res 2008;77:6-13
57. Sanchez A, Khan AS, Zaki SR, et al. Filoviridae: Marburg and Ebola viruses. In: Field's Virology. Knipe DM, Hawley PM, editors. Lippincott Williams & Wilkins, Philadelphia: PA; 2001. p. 1279-304
58. Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605-9
59. Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006;346:394-401
60. University of Pennsylvania. Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost. WO2006033672 (2006)
61. University of Pennsylvania. Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations. WO2006078279 (2006)
62. Wang D, Hevey M, Juompan LY, et al. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology 2006;353:324-32
63. Cumulative number of confirmed human cases of H5N1 avian influenza A infections reported to WHO, 2007. Available from: www.who.int/csr/ disease/avian_influenza/country/cases_table_2007_12_28/en/index.html [Last accessed 22 January 2008]
64. Van Kampen KR, Shi Z, Gao P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005;23:1029-36
65. Hoelscher MA, Jayashankar L, Garg S, et al. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin Pharmacol Therapeutics 2007;82:665-71
66. Epstein SL, Kong WP, Misplon JA, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005;23:5404-10
67. Roy S, Kobinger GP, Lin J, et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 2007;25:6845-51
68. Ertl HCJ. Rabies DNA vaccines for protection and therapeutic treatment. Expert Opin Biol Ther 2003;3:639-44
69. Ertl HCJ. Immunological insights from genetic vaccines. Virus Res 2005;111:89-92
70. Cancer Center, Sun Yat-Sen University. SARS virus vaccine with adenovirus carrier and preparation method thereof, and use of SARS virus S gene for preparation of vaccine. WO2005117961 (2005)
71. Heppner DG Jr, Kester KE, Ockenhouse CF, et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 2005;23:2243-50
72. Rasooly R, Balaban N. Trypanosome microtubule-associated protein p15 as a vaccine for the prevention of African sleeping sickness. Vaccine 2004:22:1007-15
73. Gabaglia CR, Sercarz EE, Diaz-De-Durana Y, et al. Life-long systemic protection in mice vaccinated with L major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes. Vaccine 2004;23:247-57
74. Ophorst OJ, Radosević K, Ouwehand K, et al. Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence. Vaccine 2007;25:1426-36
75. Ophorst OJ, Radosevic K, Klap JM, et al. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 2007;25:6501-10
76. Genvec, Inc./US Naval Medical Research Center. Adenoviral vector-based malaria vaccines. WO2007027860 (2007)
77. Isis Innovation Ltd. Compositions for immunizing against Mycobacterium. WO2006072787 (2006)
78. Vectorlogics, Inc. Shielded adenoviral vectors and methods of use. WO2007050128 (2007)
79. Zeng M, Xu Q, Elias M, et al. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 2007;25:7540-8
80. Shi Z, Zeng M, Yang G, et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 2001;75:11474-82
81. Worgall S, Krause A, Qiu J, et al. Protective immunity to Pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol 2007;81:13801-8
82. Cany J, Avril A, Pichard V, et al. A transgenic mouse with β-galactosidase as a fetal liver self-antigen for immunotherapy studies. J Hepatol 2007;47:396-403
83. Chen L, Liang GP, Tang XD, et al. In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus. Biochem Biophys Res Commun 2006;351:927-34
84. Kim TG. Dendrite cells transduced with recombinant adenovirus AdVCEA which generate CEA-specific cytotoxic T lymphocytes, vaccine and pharmaceutical composition comprising the same. WO2005120566 (2005)
85. Yang JY, Cao DY, Liu WC, et al. Dendritic cell generated from CD34+ hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses. Cell Immunol 2006;240:14-21
86. Pan Y, Zhang J, Zhou L, et al. In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus. Biochem Biophys Res Commun 2006;347:551-7
87. Kim HD, Jin JJ, Maxwell JA, Fukuchi K. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett 2007;112:30-8
88. Vasilevko V, Cribbs DH. Novel approaches for immunotherapeutic intervention in Alzheimer's disease. Neurochem Intl 2006;49:113-26
89. Vogels R, Zuijdgeest D, Van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003;77:8263-71
90. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004;11:351-7
91. Sumida SM, Truitt DM, Lemckert AAC, at al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immnunol 2005;174:7179-85
92. Cohen P. Immunity's yin and yang. IAVI Rep 2006;10(1):1-5
93. Lemiale F, Kong WP, Akyurek LM, et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003;77:10078-87
94. Barouch DH, Pau MG, Custers JH, et al. Immunogenicity of recombinant adenovirus seratype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004;172:6290-7
95. Lemckert AAC, Sumida SM, Holterman L, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005;79:9694-701
96. Merck & Co., Inc. Method of inducing an enhanced immune response against HIV. WO03077859 (2003)
97. Merck & Co., Inc. Method of inducing an enhanced immune response against HIV. WO03076598 (2003)
98. Duke CMP, Maguire CA, Keefer MC, et al. HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime. Vaccine 2007;25:7410-21
99. Shu Y, Winfrey S, Yang ZY, et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 2007;25:1398-408
100. Wadell G, Mei YF, Segerman A, et al. Viral vector for gene therapy. WO2002053759 (2002)
101. Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby. WO2004083418 (2004)
102. Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby. WO2006086284 (2006)
103. Merck & Co., Inc. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby. WO2004097016 (2004)
104. Bout A, Vogels R, Havenga MJE. Adenovirus-derived gene delivery vehicles comprising at least one element of adenovirus type 35. EP1054064 (2004)
105. Merck & Co., Inc. Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby. WO2006086357 (2006)
106. Mastrangeli A, Harvey BG, Yao J, et al. 'Sero-switch' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996;7:79-87
107. Schering-Plough Ltd. Recombinant and mutant adenoviruses derived of bovine adenovirus type 1. WO0061773 (2000)
108. Purdue Research Foundation. Adenoviral vectors, proteins and methods for their use. WO0050076 (2000)
109. University of Guelph. Porcine adenovirus type 5 vector and vaccine. WO0183737 (2001)
110. Instituto Di Ricerche Di Biologia Molecolare P. Angeletti SPA. Chimpanzee adenovirus vaccine carriers. WO2005071093 (2005)
111. Glaxo Group Ltd. Vaccine composition. WO2006120034 (2006)
112. University of Iowa Research Foundation. Adenovirus seratype 30 (Ad30) fiber protein and uses thereof. WO02083902 (2002)
113. Crucell Holland BV. Gene delivery vectors for stem cells. WO0229073 (2002)
114. Genvec, Inc./National Institutes of Health. Adenovirus fiber shaft composition and methods of use. WO2006044736 (2006)
115. National Institutes of Health/Genvec, Inc. Adenoviral vectors able to transduce APCs, potential use in immune response generation. WO2006039045 (2006)
116. University of Iowa Research Foundation. Receptor-targeted adenoviral vectors. WO2003050238 (2003)
117. Havenga MJ, Lemckert AA, Ophorst OJ, et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 2002;76:4612-20
118. Ophorst OJ, Kostense S, Goudsmit J, et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004;22:3035-44
119. Cornell Research Foundation, Inc./Genvec, Inc. Chimeric adenoviral coat protein and methods of using same. WO9840509 (1998)
120. Youil R, Toner TJ, Su Q, et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 2002;13:311-20
121. Roberts DM, Nanda A, Havenga MJE, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2007;441:239-43
122. Croyle MA, Le HT, Linse KD, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 2005;12:579-87
123. Sailaja G, Hogenesch H, North A, et al. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune responses. Gene Ther 2002;9:1722-9